MX2021014771A - Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. - Google Patents
Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.Info
- Publication number
- MX2021014771A MX2021014771A MX2021014771A MX2021014771A MX2021014771A MX 2021014771 A MX2021014771 A MX 2021014771A MX 2021014771 A MX2021014771 A MX 2021014771A MX 2021014771 A MX2021014771 A MX 2021014771A MX 2021014771 A MX2021014771 A MX 2021014771A
- Authority
- MX
- Mexico
- Prior art keywords
- tlr7 agonist
- capsid assembly
- hbv capsid
- combined treatment
- assembly inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se dirige a composiciones y métodos para tratar infección de virus de hepatitis B virus. En particular, la presente invención se dirige a una terapia de combinación que comprende administración de un agonista de TLR7 y un inhibidor de montaje de cápsida de HBV para el uso en el tratamiento de paciente con hepatitis B crónica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016098892 | 2016-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014771A true MX2021014771A (es) | 2022-01-18 |
Family
ID=59859071
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019002678A MX2019002678A (es) | 2016-09-13 | 2017-09-11 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. |
MX2021014771A MX2021014771A (es) | 2016-09-13 | 2019-03-07 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019002678A MX2019002678A (es) | 2016-09-13 | 2017-09-11 | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11337982B2 (es) |
EP (2) | EP3970750A1 (es) |
JP (2) | JP7101663B2 (es) |
KR (1) | KR102497701B1 (es) |
CN (1) | CN109715214B (es) |
AU (1) | AU2017326400B2 (es) |
BR (1) | BR112019004560A2 (es) |
CA (1) | CA3034185A1 (es) |
ES (1) | ES2894605T3 (es) |
IL (2) | IL264926B (es) |
MX (2) | MX2019002678A (es) |
PL (1) | PL3512556T3 (es) |
TW (1) | TWI720250B (es) |
WO (1) | WO2018050571A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016020566B1 (pt) * | 2014-03-07 | 2022-11-29 | F. Hoffmann-La Roche Ag | Novas heteroaril-diidro-pirimidinas fundidas na posição 6 para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
EP3645516A4 (en) | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
KR20200128414A (ko) * | 2018-02-28 | 2020-11-12 | 에프. 호프만-라 로슈 아게 | 간암의 치료 및 예방을 위한 7-치환된 설폰이미도일퓨린온 화합물 및 유도체 |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
WO2020125729A1 (en) | 2018-12-20 | 2020-06-25 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
WO2020193459A1 (en) | 2019-03-25 | 2020-10-01 | F. Hoffmann-La Roche Ag | Solid forms of a compound of hbv core protein allosteric modifier |
TW202122392A (zh) * | 2019-07-31 | 2021-06-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 二氫嘧啶衍生物及其於治療hbv感染或hbv誘發的疾病之用途 |
CN114423430A (zh) * | 2019-09-20 | 2022-04-29 | 豪夫迈·罗氏有限公司 | 使用核心蛋白别构调节剂治疗hbv感染的方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
WO2005085462A1 (en) | 2004-02-27 | 2005-09-15 | Dsm Ip Assets B.V. | Enzymatic preparation of an enantiomerically enriched beta-2-amino acids |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
BRPI0611435A2 (pt) | 2005-05-04 | 2010-09-08 | Pfizer Ltd | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos |
EP1926725A4 (en) | 2005-09-22 | 2010-10-06 | Scripps Research Inst | PROTEIN KINASEINHIBITORS ON ALKOXYINDOLINONE BASE |
JP2009542645A (ja) * | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
WO2009067547A1 (en) | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
PL2098526T3 (pl) | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
JP5816087B2 (ja) | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Smoアンタゴニストとしての飽和二環式複素環誘導体 |
KR101687841B1 (ko) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CA2857344C (en) * | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
CA2865259A1 (en) | 2012-03-31 | 2013-10-03 | F. Hoffmann-La Roche Ag | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CN104603125A (zh) | 2012-09-10 | 2015-05-06 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶 |
US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
BR112016020566B1 (pt) * | 2014-03-07 | 2022-11-29 | F. Hoffmann-La Roche Ag | Novas heteroaril-diidro-pirimidinas fundidas na posição 6 para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
US9962388B2 (en) | 2014-08-15 | 2018-05-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
JP2017531655A (ja) * | 2014-10-11 | 2017-10-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 感染性疾患の処置に使用するための化合物 |
CA2979490C (en) * | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
CA2982704C (en) * | 2015-05-08 | 2023-10-24 | F. Hoffmann-La Roche Ag | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
JP7013467B2 (ja) * | 2016-08-29 | 2022-01-31 | エフ.ホフマン-ラ ロシュ アーゲー | ウイルス感染の治療又は予防用の7位置換スルホンイミドイルプリノン化合物 |
-
2017
- 2017-09-11 JP JP2019513914A patent/JP7101663B2/ja active Active
- 2017-09-11 BR BR112019004560A patent/BR112019004560A2/pt unknown
- 2017-09-11 EP EP21188992.8A patent/EP3970750A1/en active Pending
- 2017-09-11 CA CA3034185A patent/CA3034185A1/en active Pending
- 2017-09-11 ES ES17767788T patent/ES2894605T3/es active Active
- 2017-09-11 PL PL17767788T patent/PL3512556T3/pl unknown
- 2017-09-11 CN CN201780054239.9A patent/CN109715214B/zh active Active
- 2017-09-11 KR KR1020197010363A patent/KR102497701B1/ko active IP Right Grant
- 2017-09-11 MX MX2019002678A patent/MX2019002678A/es unknown
- 2017-09-11 EP EP17767788.7A patent/EP3512556B1/en active Active
- 2017-09-11 AU AU2017326400A patent/AU2017326400B2/en active Active
- 2017-09-11 TW TW106130951A patent/TWI720250B/zh active
- 2017-09-11 WO PCT/EP2017/072671 patent/WO2018050571A1/en unknown
-
2019
- 2019-02-20 IL IL264926A patent/IL264926B/en unknown
- 2019-03-07 MX MX2021014771A patent/MX2021014771A/es unknown
- 2019-03-13 US US16/351,922 patent/US11337982B2/en active Active
-
2021
- 2021-10-25 IL IL287545A patent/IL287545B2/en unknown
-
2022
- 2022-07-04 JP JP2022107537A patent/JP2022130672A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PL3512556T3 (pl) | 2021-12-27 |
EP3512556B1 (en) | 2021-08-18 |
CN109715214B (zh) | 2022-03-04 |
ES2894605T3 (es) | 2022-02-15 |
BR112019004560A2 (pt) | 2019-07-02 |
EP3970750A1 (en) | 2022-03-23 |
IL287545B (en) | 2022-10-01 |
US20190298726A1 (en) | 2019-10-03 |
JP7101663B2 (ja) | 2022-07-15 |
KR20190053219A (ko) | 2019-05-17 |
WO2018050571A1 (en) | 2018-03-22 |
IL287545B2 (en) | 2023-02-01 |
IL287545A (en) | 2021-12-01 |
MX2019002678A (es) | 2019-05-20 |
CN109715214A (zh) | 2019-05-03 |
EP3512556A1 (en) | 2019-07-24 |
AU2017326400B2 (en) | 2023-03-30 |
IL264926B (en) | 2021-12-01 |
JP2022130672A (ja) | 2022-09-06 |
CA3034185A1 (en) | 2018-03-22 |
KR102497701B1 (ko) | 2023-02-09 |
US11337982B2 (en) | 2022-05-24 |
AU2017326400A1 (en) | 2019-02-21 |
TW201811371A (zh) | 2018-04-01 |
TWI720250B (zh) | 2021-03-01 |
JP2019526610A (ja) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011756A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb. | |
MX2021014771A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. | |
MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
MX2020011808A (es) | Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside. | |
PH12016501631A1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
MX2022009352A (es) | Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c. | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
AR111908A1 (es) | Composiciones terapéuticas y métodos de tratamiento de hepatitis b | |
MX2017015896A (es) | Agente anticancerigeno. | |
MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
GEP20237518B (en) | Combination therapies of hepatitis b virus (hbv)-infected individuals using parapoxvirus ovis (ppvo) and at least one further antiviral drug | |
PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
MX2022007909A (es) | Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv. | |
MX2021013594A (es) | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
EA201892348A1 (ru) | Комбинации и способы, включающие ингибитор сборки капсида | |
EA202090597A1 (ru) | Комбинированная терапия пациентов, инфицированных вирусом гепатита в (hbv), с использованием parapoxvirus ovis (ppvo) и по меньшей мере одного дополнительного противовирусного средства |